Diabetes Research and Clinical Practice, 9 (1990) 299–302
Elsevier

Author Index to Volume 9 (1990)

Abe, M., Ono, J. and Takaki, R., Effects of glucose and insulin on cultured human microvascular endothelial cells, 287
Akazawa, S., see Yokota, A., 211
Alberti, K.G.M.M., see McLarty, D.G., 219
Anderson, D.C., see Winocour, P.H., 23
Asamoah, K.A., Rohb, D.A. and Furman, B.L., Chronic chloroquine treatment enhances insulin release in rats, 273
Athaide, I., see McLarty, D.G., 219

Baba, S., see Eijri, K., 1
Baba, S., see Kuroda, N., 49
Baba, S., see Kazumi, T., 163
Balice, A.M., see Di Paolo, S., 65
Boroujerdi, M.A., see Umpleby, A.M., 89
Bottazzo, G.F., see McLarty, D.G., 219
Brandenburg, D., see Stümpel, F., 257

Capogreco, C., see Sullivan, D.R., 225
Capogreco, C., see Yue, D.K., 239
Carson, E.R., see Umpleby, A.M., 89
Caterson, I., see Sullivan, D.R., 225
Chari, S., see Mohan, V., 97
Chen, M.-S., see Tai, T.-Y., 59
Chinn, S., see Watts, G.F., 169
Chuang, L.-M., see Tai, T.-Y., 59
Circiaco, O., see Lorini, R., 279
Cockram, C.S., Pui, P.C., Keung, C.C., Moon, Y.S. and Swaminathan, R., A comparison of fructosamine and glucosylated haemoglobin measurements at a diabetic clinic, 43
Conget, J.I., Esmatjes, E., Ferrer, J., Vendrell, J., Moscoso, E. and Gomis, R., Human insulin dosage and distribution at the onset of type 1 diabetes mellitus, 251
Connis, R.T., see Mengel, M.B., 149
Cooney, G., see Sullivan, D.R., 225
Creutzfeldt, W., see Stümpel, F., 257

D'Alessio, D., see Duck, S.C., 195
D'Annunzio, G., see Lorini, R., 279
Di Giamberardino, L., see Tomlinson, D.R., 15
Dindar, A., Günöz, H. and Neyzi, O., β-Endorphin levels of children in acute stress, 245
Di Paolo, S., Lattanzzi, V., Guastamacchia, E., Vincenti, C., Balice, A.M., Montanaro, N., Nardelli, G.M. and Giorgino, R., Extreme insulin resistance due to anti-insulin receptor antibodies: a direct demonstration of autoantibody secretion by peripheral lymphocytes, 65
Draznin, B., see Murakami, K., 115
Duck, S.C., Lee, M. and D'Alessio, D., 24-42 month stability of internal blood standards for glycated hemoglobin analysis, 195
Dunbar, J.C., Reinholt, L., Henry, R.L. and Mammen, E., Platelet aggregation and disaggregation in the streptozotocin induced diabetic rat: the effect of sympathetic inhibition, 265

Eijri, K., Taniguchi, H., Morimoto, Y., Yamashiro, Y., Baba, S., Srikanta, S. and Eisenbarth, G.S., Heterogeneity of islet cell autoantibodies in terms of insulin release from rat islets and insulinoma cells, 1
Eisenbarth, G.S., see Eijri, K., 1
Esmatjes, E., see Conget, J.I., 251

Federlin, K., see Hammes, H.-P., 37
Ferrer, J., see Conget, J.I., 251
Figliomeni, B., see Tomlinson, D.R., 15
Filliatreau, G., see Tomlinson, D.R., 15
Fisher, E., see Yue, D.K., 239
Fujii, M., see Okabayashi, Y., 143
Fujisawa, T., see Okabayashi, Y., 143
Furman, B.L., see Asamoah, K.A., 273
Furukawa, S., see Hirano, T., 231

Giorgino, R., see Di Paolo, S., 65
Gomis, R., see Conget, J.I., 251
Gordon, C., see Winocour, P.H., 23
Gordon, M.J., see Mengel, M.B., 149
Guastamacchia, E., see Di Paolo, S., 65
Günöz, H., see Dindar, A., 245

Hammes, H.-P., Kiefel, V., Laube, H. and Federlin, K., Impaired agglutination of IgM resulting from non-enzymatic glycation in diabetes mellitus, 37
Hartmann, H., see Stümpel, F., 257
Hasegawa, H., see Okabayashi, Y., 143
Hashimoto, M., see Hirota, M., 179

Hassig, R., see Tomlinson, D.R., 15
Hatanaka, I., see Yasuda, H., 187
Hayashi, T., see Nanbara, S., 109
Hefferman, S., see Yue, D.K., 239
Henry, R.L., see Dunbar, J.C., 265
Hensley, W.J., see Sullivan, D.R., 225
Herman, S.J., see Mengel, M.B., 149
Hirano, T., Mamo, J.C.L., Furukawa, S., Nagano, S. and Takahashi, T., Effect of acute hyperglycemia on plasma triglyceride concentration and triglyceride secretion rate in non-fasted rats, 231
Hirata, Y., see Kodama, K., 55
Hiratsuka, M., see Hirota, M., 179
Hirota, M., Hashimoto, M., Hiratsuka, M., Ohboshi, C., Yoshimoto, S., Yano, M., Mizuno, A. and Shima, K., Alterations of plasma immunoreactive glucagon-like peptide-I behavior in non-insulin-dependent diabetics, 179

Ikari, N., see Yokota, A., 211
Ionescu-Tirgoviste, C., Pruna, S. and Mincu, I., Peripheral sympathetic neuropathy evaluated by recording the evoked electrodermal response using an impedance reactometer, 201
Iwai, M., see Kazumi, T., 163
Iwakiri, R., Nagafuchi, S., Kounnoue, E., Nakamura, M., Kikuchi, M. and Niho, Y., Immunohistochemical study of insulitis induced by multiple low doses of streptozocin in CD-1 mice, 75
Iwatani, I., see Kazumi, T., 163

Jeacock, J., see Winocour, P.H., 23

Kajiyama, S., see Kitagawa, Y., 7
Kalk, W.J., Osler, C., Taylor, D. and Panz, V.R., Prior long term glycaemic control and insulin therapy in insulin-dependent diabetic adolescents with microalbuminuria, 83
Kalsi, P., see Winocour, P.H., 23
Kanatsuna, T., see Kitagawa, Y., 7
Kano, Y., see Kitagawa, Y., 7
Kasama, T., see Kazumi, T., 163
Kawai, K., see Murayama, Y., 129
Kazumi, T., Yoshino, G., Iwai, M., Matsuba, K., Matsushita, M., Iwatani, I., Kasama, T., Yoshida, M. and Baba, S., Long-term effects of bezafibrate on in vivo VLDL-triglyceride production in the rat, 163
Keung, C.C., see Cockram, C.S., 43
Kiefel, V., see Hammes, H.-P., 37
Kikkawa, R., see Yasuda, H., 187
Kikuchi, M., see Iwakiri, R., 75
Kitagawa, Y., Kanatsuna, T., Kajiyama, S., Nakamura, N., Nakamura, Y., Kano, Y., Nakano, K., Kondo, M. and Ludvigsson, J., Islet cell surface antibodies preferentially inhibit glucose-stimulated insulin release in vitro, 7
Kobayashi, N., see Yasuda, H., 187
Kodama, K., Tomioka, M., Otani, T., Shimizu, S., Uchigata, Y. and Hirata, Y., The range of albumin concentrations in the single-void first morning urine of 1090 healthy young children, 55
Koide, H., see Nanbara, S., 109
Koide, M., see Okabayashi, Y., 143
Kondo, M., see Kitagawa, Y., 7
Kounnoue, E., see Iwakiri, R., 75
Kubal, C., see Watts, G.F., 169
Kuroda, N., Taniguchi, H., Baba, S. and Yamamoto, M., Relationship between age and autonomic neuropathy in diabetes mellitus, 49

Larizza, D., see Lorini, R., 279
Lattanzzi, V., see Di Paolo, S., 65
Laube, H., see Hammes, H.-P., 37
Lee, H.K., see Paik, H.Y., 103
Lee, M., see Duck, S.C., 195
Lin, B.J., see Tai, T.-Y., 59
Livieri, C., see Lorini, R., 279
Lorini, R., Circiaco, O., Salvatoni, A., Livieri, C., Larizza, D. and D'Annunzio, G., The influence of dietary education in diabetic children, 279
Ludvigsson, J., see Kitagawa, Y., 7

Madanagopalan, N., see Mohan, V., 97
Mammen, E., see Dunbar, J.C., 265
Mamo, J.C.L., see Hirano, T., 231
Matsuba, K., see Kazumi, T., 163
Matsushita, M., see Kazumi, T., 163
McGill, M., see Yue, D.K., 239
McLarty, D.G., Athaide, I., Bottazzo, G.F., Swai, A.M.B. and Alberti, K.G.M.M., Islet cell antibodies are not specifically associated with insulin-dependent diabetes in Tanzanian Africans, 219
McLennan, S., see Sullivan, D.R., 225
McLennan, S., see Yue, D.K., 239
Melih Altan, V., see Oztürk, Y., 123
Mengel, M.B., Connis, R.T., Gordon, M.J., Herman, S.J. and Taylor, T.R., The relationship of family dynamics/social support to patient functioning in IDDM patients on intensive insulin therapy, 149
Mincu, I., see Ionescu-Tirgoviste, C., 201
Miyake, S., see Yokota, A., 211
Mizuno, A., see Hirota, M., 179
Mohan, V., Snehalatha, S., Ramachandran, A., Chari, S., Madanagopalan, N. and Viswanatchan, M., Plasma glucagon responses in tropical fibrocalculous pancreatic diabetes, 97
Montanaro, N., see Di Paolo, S., 65
Moon, Y.S., see Cockram, C.S., 43
Morimoto, Y., see Eijri, K., 1
Moscoso, E., see Conget, J.I., 251
Murakami, K., Wilk, J., Nishida, K., Sussman, K.E. and

Draznin, B., Hep-G2 glucose transporter gene polymorphism in Caucasian, Black, Hispanic and Japanese patients with NIDDM, 115
Muruyama, Y., Kawai, K., Nakamura, S. and Yamashita, K., The endogenous insulin secretion was suppressed during insulin therapy in NIDDM patients, 129

Nagafuchi, S., see Iwakiri, R., 75
Nagano, S., see Hirano, T., 231
Nagataki, S., see Yokota, A., 211
Nakamura, M., see Iwakiri, R., 75
Nakamura, N., see Kitagawa, Y., 7
Nakamura, S., see Murayama, Y., 129
Nakamura, Y., see Kitagawa, Y., 7
Nakamura, T., see Okabayashi, Y., 143
Nakanishi, T., see Yokota, A., 211
Nakano, K., Kitagawa, Y., 7
Nanbara, S., Tanaka, K., Koide, H., Tanaka, T. and Hayashi, T., Changes on levels of B_6 vitamin and aminotransferase in the liver of diabetic animals, 109
Nardelli, G.M., see Di Paolo, S., 65
Neyzi, O., see Dindar, A., 245
Nicks, J., see Sullivan, D.R., 225
Niho, Y., see Iwakiri, R., 75
Nishida, K., see Murakami, K., 115

Ohboshi, C., see Hirota, M., 179
Okabayashi, Y., Tani, S., Fujisawa, T., Koide, M., Hasegawa, H., Nakamura, T., Fujii, M. and Otsuki, M., Effect of *Gymnema sylvestre*, R.Br. on glucose homeostasis in rats, 143
Ono, J., see Abe, M., 287
Osler, C., see Kalk, W.J., 83
Otani, T., see Kodama, K., 55
Otsuki, M., see Okabayashi, Y., 143
Oztürk, Y., Yildizoglu-Ari, N., Ozüari, A., Tanju Ozcelikay, A. and Melih Altan, V., Decreased B-adrenergic responses of rat small intestine due to non-insulin-dependent diabetes, 123
Ozüari, A., see Oztürk, Y., 123

Paik, H.Y. and Lee, H.K., Korean food exchange systems, 103
Panz, V.R., see Kalk, W.J., 83
Pruna, S., see Ionescu-Tirgoviste, C., 201
Pui, P.C., see Cockram, C.S., 43

Ramachandran, A., see Mohan, V., 97
Reinholt, L., see Dunbar, J.C., 265
Rohb, D.A., see Asamoah, K.A., 273

Salvatoni, A., see Lorini, R., 279
Scobie, I.N., see Umpleby, A.M., 89
Shigeta, Y., see Yasuda, H., 187
Shima, K., see Hirota, 179
Shimizu, S., see Kodama, K., 55
Snehalatha, S., see Mohan, V., 97
Sonksen, P.H., see Umpleby, A.M., 89
Sonobe, M., see Yasuda, H., 187
Srikanta, S., see Eijri, K., 1
Stümpel, F., Hartmann, H., Brandenburg, D. and Creutzfeldt, W., In vivo metabolic activity of des-(B26-B30)-insulin-B25-amide and related analogues in the rat, 257
Sullivan, D.R., Yue, D.K., Capogreco, C., McLennan, S., Nicks, J., Cooney, G. Caterson, I., Turtle, J.R. and Hensley, W.J., The effects of dietary $n-3$ fatty acid in animal models of type 1 and type 2 diabetes, 225
Sussman, K.E., see Murakami, K., 115
Swai, A.M.B., see McLarty, D.G., 219
Swaminathan, R., see Cockram, C.S., 43

Tai, J. and Tze, W.J., Evaluation of icro-Bumintest reagent tablets for screening of microalbuminuria, 137
Tai, T.-Y., Chuang, L.-M., Tseng, C.-H., Wu, H.-P., Chen, M.-S. and Lin, B.J., Microalbuminuria and diabetic complications in Chinese non-insulin-dependent diabetic patients: a prospective study, 59
Takahashi, T., see Hirano, T., 231
Takaki, R., see Abe, M., 287
Tanaka, K., see Nanbara, S., 109
Tanaka, T., see Nanbara, S. 109
Tani, S., see Okabayashi, Y., 143
Taniguchi, H., see Eijri, K., 1
Taniguchi, H., see Kuroda, N., 49
Taniguchi, Y., see Yasuda, H., 187
Tanju Ozcelikay, A., see Oztürk, Y., 123
Taylor, D., see Kalk, W.J., 83
Taylor, T.R., see Mengel, M.B., 149
Tomioka, M., see Kodama, K., 55
Tomlinson, D.R., Filliatrea, G., Figliomeni, B., Hassig, R., Di Giamberardino, L. and Willars, G.B., Proteins of slow axonal transport in sciatic motoneurons of rats with streptozotocin-induced diabetes of galactosaemia, 15
Tseng, C.-H., see Tai, T.-Y., 59
Turtle, J.R., see Sullivan, D.R., 225
Turtle, J.R., see Yue, D.K., 239
Tze, W.J., see Tai, J., 137

Uchigata, Y., see Kodama, K., 55
Ueda, Y., see Yokota, A., 211
Umpleby, A.M., Scobie, I.N., Boroujerdi, M.A., Carson, E.R. and Sonksen, P.H., Diurnal variation in glucose and leucine metabolism in non-insulin-dependent diabetes, 89

Vendrell, J., see Conget, J.I., 251
Vincenti, C., see Di Paolo, S., 65
Viswanathan, M., see Mohan, V., 97

Watts, G.F., Kubal, C. and Chinn, S., Long-term variation of urinary albumin excretion in insulin-dependent diabetes mellitus: some practical recommendations for monitoring microalbuminuria, 169

Wilk, J., see Murakami, K., 115
Willars, G.B., see Tomlinson, D.R., 15
Winocour, P.H., Jeacock, J., Kalsi, P., Gordon, C. and Anderson, D.C., The relevance of pesistent C-peptide secretion in type 1 (insulin-dependent) diabetes mellitus to glycaemic control and diabetic complications, 23
Wu, H.-P., see Tai, T.-Y., 59

Yamaguchi, Y., see Yokota, A., 211
Yamamoto, M., see Kuroda, N., 49
Yamashiro, Y., see Eijri, K., 1
Yamashita, K., see Murayama, Y., 129
Yamashita, M., see Yasuda, H., 187
Yano, M., see Hirota, M., 179
Yasuda, H., Taniguchi, Y., Yamashita, M., Kobayashi, N., Sonobe, M., Hatanaka, I., Kikkawa, R. and Shigeta, Y., Morphological characteristics of dermal diabetic microangiopathy, 187
Yildizoglu-Ari, N., see Oztürk, Y., 123
Yokota, A., Yamaguchi, Y., Ueda, Y., Nakanishi, T., Ikari, N., Akazawa, S., Miyake, S. and Nagataki, S., Comparison of islet cell antibodies, islet cell surface antibodies and anti-bovine serum albumin antibodies in type 1 diabetes, 211
Yoshida, M., see Kazumi, T., 163
Yoshimoto, S., see Hirota, M., 179
Yoshino, G., see Kazumi, T., 163
Yue, D.K., McLennan, S., McGill, M., Fisher, E., Hefferman, S., Capogreco, C. and Turtle, J.R., Abnormalities of ascorbic acid metabolism and diabetic control: differences between diabetic patients and diabetic rats, 239
Yue, D.K., see Sullivan, D.R., 225

Diabetes Research and Clinical Practice, 9 (1990) 303–306
Elsevier

Key Word Index to Volume 9 (1990)

α-Adrenergic inhibition
– Streptozotocin diabetes; Platelet aggregation; Platelet size, 265
β-Adrenoceptor
– Alloxan; Gastro-intestinal tract, 123
African
– Islet cell antibody; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Tanzania; Autoantibody, 219
Aging
– Autonomic neuropathy; Cardiac beat-to-beat variation; Pupil, 49
Agloroquine
– Insulin release; β-Cells; Streptozotocin; Glucose homeostasis; Pancreatic islets, 273
Alanine aminotransferase (ALT)
– Vitamin B_6; Pyridoaxime; Aspartate aminotransferase (AST); Liver, diabetic, 109
Alcroalbuminuria
– Diabetic complication, 59
Alloxan
– β-Adrenoceptor; Gastro-intestinal tract, 123
Anti-bovine serum albumin antibody
– Islet cell antibody; Islet cell surface antibody; Type 1 diabetes; Rat insulinoma cell, 211
Anti-insulin receptor antibody
– Extreme insulin resistance; ELISA-spot assay, 65
Ascorbic acid
– Vitamin; Free radical; Glycosylated haemoglobin; Collagen; Diabetic complication, 239
Aspartate aminotransferase (AST)
– Vitamin B_6; Pyridoaxime; Alanine aminotransferase (ALT); Liver, diabetic, 109
Autoantibody
– Islet cell antibody; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Tanzania; African, 219
Autonomic neuropathy
– Aging; Cardiac beat-to-beat variation; Pupil, 49
Autonomic conduction velocity
– Sympathetic neuropathy; Electrodermal response, 201
Axonal transport
– Galactosaemia; Neurofilament; Tubulin, 15

Basement membrane thickness
– Diabetic microangiopathy; Skin biopsy; Endothelial cell, 187
Bezafibrate
– VLDL-triglyceride production; Rat plasma, 163

Cardiac beat-to-beat variation
– Aging; Autonomic neuropathy; Pupil, 49
β-Cells
– Agloroquine; Insulin release; Streptozotocin; Glucose homeostasis; Pancreatic islets, 273
Child
– Endorphin; β-Endorphin; Stress; Hyperglycaemia; Insulin, 245
Children
– Microalbuminuria; Protein, 137
Collagen
– Ascorbic acid; Vitamin; Free radical; Glycosylated haemoglobin; Diabetic complication, 239
Complication
– C-peptide; Glycaemic; GSA; Fructosamine; HbA_1; Peripheral vascular disease; Insulin; Proliferation retinopathy, 23
Cortisol
– Glucose; Leucine; Insulin; Growth hormone, 89

Diabetes
– *n* – 3 fatty acid; Membrane composition, 225
Diabetes mellitus
– Dietary treatment, 279
Diabetic complication
– Alcroalbuminuria, 59
Diabetic complication
– Ascorbic acid; Vitamin; Free radical; Glycosylated haemoglobin; Collagen, 239
Diabetic microangiopathy
– Skin biopsy; Basement membrane thickness; Endothelial cell, 187
Diabetic microangiopathy
– Human microvascular endothelial cells; Glucose toxicity; Insulin toxicity; Na^+/K^+ pump activity, 287
Dietary treatment
– Diabetes mellitus, 279

Dosage
– Human insulin; Type 1 diabetes mellitus, 251

Electrodermal response
– Sympathetic neuropathy; Autonomic conduction velocity, 201
ELISA-spot assay
– Extreme insulin resistance; Anti-insulin receptor antibody, 65
Endorphin
– β-Endorphin; Child; Stress; Hyperglycaemia; Insulin, 245
β-Endorphin
– Endorphin; Child; Stress; Hyperglycaemia; Insulin, 245
Endothelial cell
– Diabetic microangiopathy; Skin biopsy; Basement membrane thickness, 187
Euglycaemic clamping
– Insulin action; Insulin analogue; Glucose metabolism, 257
Extreme insulin resistance
– Anti-insulin receptor antibody; ELISA-spot assay, 65

Fatty acid $n-3$
– Diabetes; Membrane composition, 225
Free radical
– Ascorbic acid; Vitamin; Glycosylated haemoglobin; Collagen; Diabetic complication, 239
Fructosamine
– C-peptide; Glycaemic; GSA; HbA_1; Complication; Peripheral vascular disease; Insulin; Proliferation retinopathy, 23
Fructosamine
– Glycosylated haemoglobin, 43

Galactosaemia
– Axonal transport; Neurofilament; Tubulin, 15
Gastro-intestinal tract
– Alloxan; β-Adrenoceptor, 123
Gene
– Glucose transporter; RFLP, 115
Glucagon response
– Tropical fibrocalculous pancreatic diabetes; Ketosis resistance, 97
Glucagon-like peptide-1
– Pancreatic glucagon; Oral glucose-tolerance test; Non-insulin-dependent diabetes, 179
Glucose
– Islet cell surface antibody; Insulin release; Rat islet, 7
Glucose
– Leucine; Insulin; Cortisol; Growth hormone, 89
Glucose clamp
– Hyperglycemia; Triglyceride; Insulin; Rat, 231
Glucose homeostasis
– Agloroquine; Insulin release; β-Cells; Streptozotocin; Pancreatic islets, 273
Glucose metabolism
– Insulin action; Insulin analogue; Euglycaemic clamping, 257
Glucose toxicity
– Human microvascular endothelial cells; Diabetic microangiopathy; Insulin toxicity; Na^+/K^+ pump activity, 287
Glucose transporter
– Gene; RFLP, 115
Glycaemic
– C-peptide; GSA; Fructosamine; HbA_1; Complication; Peripheral vascular disease; Insulin; Proliferation retinopathy, 23
Glycaemic control
– Microalbuminuria, 83
Glycated hemoglobin analyses
– Internal blood standard; Stability, long-term, 195
Glycosylated haemoglobin
– Fructosamine, 43
Glycosylated haemoglobin
– Ascorbic acid; Vitamin; Free radical; Collagen; Diabetic complication, 239
Growth hormone
– Glucose; Leucine; Insulin; Cortisol, 89
GSA
– C-peptide; Glycaemic; Fructosamine; HbA_1; Complication; Peripheral vascular disease; Insulin; Proliferation retinopathy, 23
Gymnema sylvestre R.Br.
– Serum glucose concentration; Immunoreactive insulin (IRI) level; Pancreatic IRI content; Streptozocin-induced mildly diabetic rat, 143

HbA_1
– C-peptide; Glycaemic; GSA; Fructosamine; Complication; Peripheral vascular disease; Insulin; Proliferation retinopathy, 23
Human insulin
– Dosage; Type 1 diabetes mellitus, 251
Human microvascular endothelial cells
– Diabetic microangiopathy; Glucose toxicity; Insulin toxicity; Na^+/K^+ pump activity, 287
Humoral immunity
– Streptozocin; Insulitis, 75
Hyperglycaemia
– Endorphin; β-Endorphin; Child; Stress; Insulin, 245
Hyperglycemia
– Triglyceride; Insulin; Glucose clamp; Rat, 231

ICA
– Insulin; RINr; Release; Islet of Langerhans, 1
IgM-ABO agglutination
– Non-enzymatic glycation; Immunoglobulin; Quantification, 37
Immunoglobulin
– Non-enzymatic glycation; Quantification; IgM-ABO agglutination, 37

Immunoreactive insulin (IRI) level
– Serum glucose concentration; Pancreatic IRI content; Streptozocin-induced mildly diabetic rat; *Gymnema sylvestre* R.Br., 143
Insulin
– ICA; RINr; Release; Islet of Langerhans, 1
Insulin
– C-peptide; Glycaemic; GSA; Fructosamine; HbA_1; Complication; Peripheral vascular disease; Proliferation retinopathy, 23
Insulin
– Glucose; Leucine; Cortisol; Growth hormone, 89
Insulin
– Hyperglycemia; Triglyceride; Glucose clamp; Rat, 231
Insulin
– Endorphin; β-Endorphin; Child; Stress; Hyperglycaemia, 245
Insulin action
– Insulin analogue; Glucose metabolism; Euglycaemic clamping, 257
Insulin analogue
– Insulin action; Glucose metabolism; Euglycaemic clamping, 257
Insulin release
– Islet cell surface antibody; Glucose; Rat islet, 7
Insulin release
– Agloroquine; β-Cells; Streptozotocin; Glucose homeostasis; Pancreatic islets, 273
Insulin secretion
– Urinary C-peptide; Insulin therapy, 129
Insulin therapy
– Insulin secretion; Urinary C-peptide, 129
Insulin therapy
– Patient functioning; Insulin-dependent diabetes mellitus, 149
Insulin toxicity
– Human microvascular endothelial cells; Diabetic microangiopathy; Glucose toxicity; Na^+/K^+ pump activity, 287
Insulin-dependent diabetes mellitus
– Insulin therapy; Patients functioning, 149
Insulin-dependent diabetes mellitus
– Variation of albumin excretion; Re-screening patients for microalbuminuria, 169
Insulin-dependent diabetes mellitus
– Islet cell antibody; Non-insulin-dependent diabetes mellitus; Tanzania; African; Autoantibody, 219
Insulitis
– Streptozocin; Humoral immunity, 75
Internal blood standard
– Glycated hemoglobin analyses; Stability, long-term, 195
Islet cell surface antibody
– Insulin release; Glucose; Rat islet, 7
Islet cell antibody
– Islet cell surface antibody; Anti-bovine serum albumin antibody; Type 1 diabetes; Rat insulinoma cell, 211
Islet cell surface antibody
– Islet cell antibody; Anti-bovine serum albumin antibody; Type 1 diabetes; Rat insulinoma cell, 211
Islet cell antibody
– Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Tanzania; African; Autoantibody, 219
Islet of Langerhans
– Insulin; ICA; RINr; Release, 1

Ketosis resistance
– Tropical fibrocalculous pancreatic diabetes; Glucagon response, 97

Leucine
– Glucose; Insulin; Cortisol; Growth hormone, 89
Liver, diabetic
– Vitamin B_6; Pyridoaxime; Aspartate aminotransferase (AST); Alanine aminotransferase (ALT), 109

Membrane composition
– Diabetes; *n* – 3 fatty acid, 225
Microalbuminuria
– Glycaemic control, 83
Microalbuminuria
– Protein; Children, 137

Na^+/K^+ pump activity
– Human microvascular endothelial cells; Diabetic microangiopathy; Glucose toxicity; Insulin toxicity, 287
Neurofilament
– Axonal transport; Galactosaemia; Tubulin, 15
Non-enzymatic glycation
– Immunoglobulin; Quantification; IgM-ABO agglutination, 37
Non-insulin-dependent diabetes
– Glucagon-like peptide-1; Pancreatic glucagon; Oral glucose-tolerance test, 179
Non-insulin-dependent diabetes mellitus
– Islet cell antibody; Insulin-dependent diabetes mellitus; Tanzania; African; Autoantibody, 219

Oral glucose-tolerance test
– Glucagon-like peptide-1; Pancreatic glucagon; Non-insulin-dependent diabetes, 179

Pancreatic IRI content
– Serum glucose concentration; Immunoreactive insulin (IRI) level; Streptozocin-induced mildly diabetic rat; *Gymnema sylvestre* R.Br., 143
Pancreatic glucagon
– Glucagon-like peptide-1; Oral glucose-tolerance test; Non-insulin-dependent diabetes, 179
Pancreatic islets
– Agloroquine; Insulin release; β-Cells; Streptozotocin; Glucose homeostasis, 273
Patients functioning
– Insulin therapy; Insulin-dependent diabetes mellitus, 149

C-peptide
– Glycaemic; GSA; Fructosamine; HbA_1; Complication; Peripheral vascular disease; Insulin; Proliferation retinopathy, 23
Peripheral vascular disease
– C-peptide; Glycaemic; GSA; Fructosamine; HbA_1; Complication; Insulin; Proliferation retinopathy, 23
Platelet aggregation
– Streptozotocin diabetes; α-Adrenergic inhibition; Platelet size, 265
Platelet size
– Streptozotocin diabetes; α-Adrenergic inhibition; Platelet aggregation, 265
Proliferation retinopathy
– C-peptide; Glycaemic; GSA; Fructosamine; HbA_1; Complication; Peripheral vascular disease; Insulin, 23
Protein
–Microalbuminuria; Children, 137
Pupil
– Aging; Autonomic neuropathy; Cardiac beat-to-beat variation, 49
Pyridoaxime
– Vitamin B_6; Aspartate aminotransferase (AST); Alanine aminotransferase (ALT); Liver, diabetic, 109

Quantification
– Non-enzymatic glycation; Immunoglobulin; IgM-ABO agglutination, 37

Rat
– Hyperglycemia; Triglyceride; Insulin; Glucose clamp, 231
Rat insulinoma cell
– Islet cell antibody; Islet cell surface antibody; Anti-bovine serum albumin antibody; Type 1 diabetes, 211
Rat islet
– Islet cell surface antibody; Insulin release; Glucose, 7
Rat plasma
– Bezafibrate; VLDL-triglyceride production, 163
Re-screening patients for microalbuminuria
– Insulin-dependent diabetes mellitus; Variation of albumin excretion, 169
Release
– Insulin; ICA; RINr; Islet of Langerhans, 1
RFLP
– Glucose transporter; Gene, 115
RINr
– Insulin; ICA; Release; Islet of Langerhans, 1

Serum glucose concentration
– Immunoreactive insulin (IRI) level; Pancreatic IRI content; Streptozocin-induced mildly diabetic rat; *Gymnema sylvestre* R.Br., 143
Single-void first morning urine
– Turbidimetry immunoassay method, 55
Skin biopsy
– Diabetic microangiopathy; Basement membrane thickness; Endothelial cell, 187
Stability, long-term
– Internal blood standard; Glycated hemoglobin analyses, 195
Streptozocin
Insulitis; Humoral immunity, 75
Streptozocin-induced mildly diabetic rat
– Serum glucose concentration; Immunoreactive insulin (IRI) level; Pancreatic IRI content; *Gymnema sylvestre* R.Br., 143
Streptozotocin diabetes
– α-Adrenergic inhibition; Platelet aggregation; Platelet size, 265
Streptozotocin
– Agloroquine; Insulin release; β-Cells; Glucose homeostasis; Pancreatic islets, 273
Stress
– Endorphin; β-Endorphin; Child; Hyperglycaemia; Insulin, 245
Sympathetic neuropathy
– Electrodermal response; Autonomic conduction velocity, 201

Tanzania
– Islet cell antibody; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; African; Autoantibody, 219
Triglyceride
– Hyperglycemia; Insulin; Glucose clamp; Rat, 231
Tropical fibrocalculous pancreatic diabetes
– Glucagon response; Ketosis resistance, 97
Tubulin
– Axonal transport; Galactosaemia; Neurofilament, 15
Turbidimetry immunoassay method
– Single-void first morning urine, 55
Type 1 diabetes
– Islet cell antibody; Islet cell surface antibody; Anti-bovine serum albumin antibody; Rat insulinoma cell, 211
Type 1 diabetes mellitus
– Human insulin; Dosage, 251

Urinary C-peptide
– Insulin secretion; Insulin therapy, 129

Variation of albumin excretion
– Insulin-dependent diabetes mellitus; Re-screening patients for microalbuminuria, 169
Vitamin
– Ascorbic acid; Free radical; Glycosylated haemoglobin; Collagen; Diabetic complication, 239
Vitamin B_6
– Pyridoaxime; Aspartate aminotransferase (AST); Alanine aminotransferase (ALT); Liver, diabetic, 109
VLDL-triglyceride production
– Bezafibrate; Rat plasma, 163